People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35222
- Alabama (Site ID: 31788)
-
接触:
- Heather Logan
- 电话号码:205-934-6774
- 邮箱:heatherlogan@uabmc.edu
-
-
California
-
Los Angeles、California、美国、90035
- University of California, Los Angeles CARE Center (Site ID: 601)
-
接触:
- Aleen Khodabakhshian
- 电话号码:310-557-3798
- 邮箱:akhodabakhshian@mednet.ucla.edu
-
San Diego、California、美国、92103
- UCSD Antiviral Research Center (Site ID: 701)
-
接触:
- Dawn Rosenblum
- 电话号码:619-543-8080
- 邮箱:drosenblum@health.ucsd.edu
-
San Francisco、California、美国、94110
- University of California, San Francisco (Site ID: 801)
-
接触:
- Jay Dwyer
- 电话号码:415-502-5748
- 邮箱:jay.dwyer@ucsf.edu
-
Torrance、California、美国、90502-2052
- Harbor University of California Los Angeles Center (Site ID: 603)
-
接触:
- Mario Guerrero
- 电话号码:323-457-1459
- 邮箱:mguerrero@lundquist.org
-
-
Colorado
-
Aurora、Colorado、美国、80045
- University of Colorado Hospital (Site ID: 6101)
-
接触:
- Nicola Haakonsen
- 电话号码:303-724-5931
- 邮箱:nicola.haakonsen@cuanschutz.edu
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20032
- Whitman-Walker Institute, Inc. (Site ID: 21791)
-
接触:
- Avery Wimpelberg
- 电话号码:202-797-3589
- 邮箱:awimpelberg@whitman-walker.org
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Northwestern University (Site ID: 2701)
-
接触:
- Sherryl L Wolfe
- 电话号码:312-695-4997
- 邮箱:s-wolfe@northwestern.edu
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- Johns Hopkins University (Site ID: 201)
-
接触:
- Rebecca L Becker
- 电话号码:410-614-4036
- 邮箱:rbecke22@jhmi.edu
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital (Site ID: 101)
-
接触:
- Amy Sbrolla
- 电话号码:617-726-5598
- 邮箱:asbrolla@mgh.harvard.edu
-
Boston、Massachusetts、美国、02115
- Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
-
接触:
- Hannah Jordan
- 电话号码:617-732-4785
- 邮箱:hcjordan@bwh.harvard.edu
-
-
New Jersey
-
Newark、New Jersey、美国、07103
- New Jersey Medical School Clinical Research Center (Site ID: 31786)
-
接触:
- Christie Lyn Costanza
- 电话号码:972-972-9069
- 邮箱:costancl@njms.rutgers.edu
-
-
New York
-
New York、New York、美国、10010
- Weill Cornell Chelsea (Site ID: 7804)
-
接触:
- Mauricio Vergara
- 电话号码:212-746-7204
- 邮箱:mav9177@med.cornell.edu
-
New York、New York、美国、10010
- Weill Cornell Uptown (Site ID: 7803)
-
接触:
- Keisha Ballentine-Cargill
- 电话号码:212-746-7804
- 邮箱:keb4006@med.cornell.edu
-
New York、New York、美国、10032
- Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
-
接触:
- Brett T Gray
- 电话号码:212-305-1570
- 邮箱:bg2168@cumc.columbia.edu
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599-7215
- Chapel Hill (Site ID: 3201)
-
接触:
- Erin Elizabeth Hoffman
- 电话号码:919-843-0720
- 邮箱:erin_hoffman@med.unc.edu
-
Greensboro、North Carolina、美国、27401-1020
- Greensboro (Site ID: 3203)
-
接触:
- Kelly Phillips
- 电话号码:336-832-7297
- 邮箱:kelly.phillips@conehealth.com
-
-
Ohio
-
Cincinnati、Ohio、美国、45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
接触:
- Michelle Saemann
- 电话号码:513-584-2245
- 邮箱:saemanmd@ucmail.uc.edu
-
Cleveland、Ohio、美国、44106
- Case Clinical Research Site (Site ID: 2501)
-
接触:
- Julie Pasternak
- 电话号码:216-844-2738
- 邮箱:pasternak.julie@clevelandactu.org
-
Columbus、Ohio、美国、43210
- Ohio State University (Site ID: 2301)
-
接触:
- Lindsay Summers
- 电话号码:614-293-8529
- 邮箱:lindsay.summers@osumc.edu
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15213
- University of Pittsburgh (Site ID: 1001)
-
接触:
- Stacey Edick
- 电话号码:412-383-1748
- 邮箱:edicksm2@upmc.edu
-
-
Tennessee
-
Nashville、Tennessee、美国、37204
- Vanderbilt Therapeutics (VT) (Site ID: 3652)
-
接触:
- Beverly Woodward
- 电话号码:615-936-8516
- 邮箱:beverly.o.woodward@vumc.org
-
-
Texas
-
Houston、Texas、美国、77030
- Houston Advancing Research Team (Site ID: 31473)
-
接触:
- Maria Laura Martinez
- 电话号码:713-500-6718
- 邮箱:maria.l.martinez@uth.tmc.edu
-
-
Washington
-
Seattle、Washington、美国、98104
- University of Washington Positive Research (Site ID: 1401)
-
接触:
- Allysson Angeldekao
- 电话号码:503-715-7324
- 邮箱:allysson@uw.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Documented HIV-1 infection
-
Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
-
HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
-
Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
-
At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
-
Adequate laboratory parameters within 60 days prior to study entry:
- Absolute neutrophil count >600/mm3
- Hemoglobin ≥7.0 g/dL
- Platelet count >50,000/μL
- AST and ALT ≤3 × upper limit of normal
- Estimated glomerular filtration rate >15 mL/min/1.73 m²
-
For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
-
Ability and willingness to provide informed consent
-
Connected to a medical clinic with access to HIV care and antiretroviral therapy
Exclusion Criteria:
- Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
- Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
- Child-Pugh Class C cirrhosis
- No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
- Prior use of lenacapavir
- Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
- Serious medical or psychiatric condition
- Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
- Current pregnancy or breastfeeding
- Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Long-Acting Lenacapavir Plus Long-Acting Cabotegravir
|
Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation. Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses. Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
大体时间:Baseline through Week 48
|
Baseline through Week 48
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
大体时间:Week 48
|
Week 48
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
大体时间:Week 48
|
Week 48
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
大体时间:Week 48
|
Week 48
|
|
|
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
大体时间:Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
大体时间:Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
大体时间:Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
大体时间:Week 96
|
Week 96
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
大体时间:Week 96
|
Week 96
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
大体时间:Week 96
|
Week 96
|
|
|
Percentage of on-time long-acting injections
大体时间:Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
大体时间:Baseline through Week 48 and through Week 96
|
Baseline through Week 48 and through Week 96
|
|
|
Plasma trough concentrations of lenacapavir and cabotegravir
大体时间:Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Change in CD4 cell count from baseline
大体时间:Week 48 and Week 96
|
Week 48 and Week 96
|
|
|
Participant-reported treatment satisfaction
大体时间:Week 48 and Week 96
|
HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment. |
Week 48 and Week 96
|
|
Change in quality-of-life scores from baseline
大体时间:Week 48 and Week 96
|
Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life. |
Week 48 and Week 96
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
大体时间:Week 48 and Week 96
|
Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Week 48 and Week 96
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
大体时间:Baseline through Week 48
|
Baseline through Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
大体时间:Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
大体时间:Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
大体时间:Week 48
|
Week 48
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- A5431
- 39159 (其他标识符:DAIDS-ES ID)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data that underlie results in the publication after deidentification
IPD 共享时间框架
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
IPD 共享访问标准
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.